Vaccine language changes in paediatric and pregnancy recommendations

Further to recent changes to vaccine status across the recommendations for adults with mild COVID-19, the following paediatric and pregnancy recommendations have now been updated:

• Nirmatrelvir plus ritonavir (Paxlovid) for children and adolescents – consensus
• Remdesivir (Veklury) for children and adolescents – consensus, mild
• Sotrovimab (Xevudy) for children and adolescents – consensus
• Tixagevimab plus cilgavimab (Evusheld) for children and adolescents – consensus
• Sotrovimab (Xevudy) for pregnant women – conditional and consensus

Clinicians are now encouraged to make treatment decisions based on an overall assessment of the likelihood of progression to severe disease, including whether an individual has received a COVID vaccine dose, or had a SARS-CoV-2 infection, in the past 6 months.

Changes to these recommendations have also been reflected in our decision tool and flowcharts.